Oncotelic Therapeutics issues $178,410 convertible note to Pacific Pier Capital with 500,000 commitment shares

Oncotelic Therapeutics, Inc.

Gross principal $178,410; net proceeds ~$150,000 after 12% OID and $7,000 legal fee.
Note convertible at $0.06/share or 85% of lowest traded price in prior 10 trading days.
500,000 commitment shares of common stock issued to Pacific Pier as additional consideration.
Matures one year from August 3, 2026; 12% interest; 12% original issue discount.
Prepayment allowed within first six months with three trading days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.